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VEGF is the key growth factor regulating arterial
morphogenesis. However, molecular events involved
in this process have not been elucidated. Synectin
null mice demonstrate impaired VEGF signaling and
a marked reduction in arterial morphogenesis. Here,
we show that this occurs due to delayed trafficking
of VEGFR2-containing endosomes that exposes
internalized VEGFR2 to selective dephosphorylation
by PTP1b on Y1175 site. Synectin involvement in
VEGFR2 intracellular trafficking requires myosin-VI,
and myosin-VI knockout in mice or knockdown in
zebrafish phenocopy the synectin null phenotype.
Silencing of PTP1b restores VEGFR2 activation
and significantly recovers arterial morphogenesis in
myosin-VI/ knockdown zebrafish and synectin/
mice. We conclude that activation of the VEGF-
mediated arterial morphogenesis cascade requires
phosphorylation of the VEGFR2 Y1175 site that is
dependent on trafficking of internalized VEGFR2
away from the plasma membrane via a synectin-
myosin-VI complex. This key event in VEGF signaling
occurs at an intracellular site and is regulated by
a novel endosomal trafficking-dependent process.
INTRODUCTION
VEGF plays a key role in arterial morphogenesis both during
development and in the adult organism. While three recep-
tors—VEGF-R1 (Flt-1), VEGFR2 (Flk-1), and neuropilin-1—bind
VEGF-A, VEGFR2 signaling is considered crucial to vascular
formation. In particular, phosphorylation of Y1175 in the VEGFR2
cytoplasmic domain is a key event, as replacement of the
VEGFR2 gene with a VEGFR2 construct carrying a single
Y1175F mutation results in failure of vasculogenesis and embry-
onic lethality (Sakurai et al., 2005). The sequence of events
involved in VEGF-dependent VEGFR2 activation and subsequent
signaling is thus thought to include the conventional steps
of a growth factor binding to its tyrosine kinase receptor on
the plasma cell membrane, followed by receptor dimerization,Deveactivation, and assembly of a membrane-proximal signaling
complex.
Previously, we have described that deletion of synectin
(gipc1), a single PDZ-domain scaffold protein, results in
decreased arterial morphogenesis and branching and that
synectin/ endothelial cells demonstrate reduced sensitivity
to VEGF stimulation (Chittenden et al., 2006). Synectin is a widely
expressed protein isolated simultaneously by various laborato-
ries as a binding partner of RGS-GAIP(De Vries et al., 1998),
neuropilin-1 (Cai and Reed, 1999), semaphorin-4C (Wang
et al., 1999), and syndecan-4 (Gao et al., 2000), among others.
Its function remains unclear, but it can control cell migration
(Gao et al., 2000; Tkachenko et al., 2006), intracellular trafficking
(Dance et al., 2004), and cell adhesion (Lanahan et al., 2006).
Intracellular trafficking and endocytosis appear to be particularly
important aspects of synectin function, as suggested by recent
studies (Salikhova et al., 2008; Varsano et al., 2006)
Of particular interest is synectin binding to myosin-VI, a retro-
grade motor involved in endosome transport (Naccache et al.,
2006), suggesting the possibility that the synectin-myosin-VI
dependent regulation of trafficking of a newly internalized receptor
could potentially regulate its signaling. While the possibility of an
intracellular site of signaling for VEGFR2 has been suggested
(Lampugnani et al., 2006), the molecular events controlling
VEGFR2 signaling from an endosome remain unknown.
Since arterial morphogenesis has been linked to VEGF, we
examined in detail various events following VEGF stimulation of
synectin/ endothelial cells. We find that while VEGFR2 binding
of VEGF-A165 and subsequent cellular uptake of the VEGF-
VEGFR2 complex proceeds normally, VEGFR2 fails to enter the
early endosomal compartment, remaining in close proximity to
the plasma cell membrane. The trafficking of internalized VEGFR2
from the plasma membrane requires formation of the synectin-
myosin-VI complex, and disruption of myosin-VI expression
phenocopies synectin deletion. Abnormal VEGFR2 trafficking
leads to decreased phosphorylation of the crucial Y1775 site and
reduced activation of downstream signaling via PLCg/MAPK
and PI3-Kinase/Akt pathways. This, in turn, occurs due to activity
of a small intracellular tyrosine phosphatase PTP1b as suppres-
sion of PTP1b expression restores VEGF signaling in this system.
Thus, synectin-myosin-VI-dependent trafficking of VEGFR2
plays a key role in the regulation of arterial morphogenesis by
moving the VEGFR2 containing endosomes away from PTP1b-
rich periplasma cell membrane environment.lopmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Inc. 713
Figure 1. VEGF-A Signaling in Synectin/
Primary Endothelial Cells
(A and B) ERK activation. (A) Western blotting of
total cell lysates isolated from synectin+/+ and /
endothelial cells. Confluent, serum-starved cells
were stimulated for the times indicated with
50 ng/ml VEGF-A. Phosphorylation of p44/42
MAP kinase in response to VEGF-A is reduced in
synectin/ cells relative to synectin+/+ cells. (B)
Quantification of ERK activation in four indepen-
dent experiments (mean ± SD, *p < 0.05).
(C and D) VEGF receptor expression. Expression
of VEGFR1 and VEGFR2 in synectin+/+ and /
AEC. (C) Western blotting of total cell lysates
following cell-surface biotinylation and precipita-
tion of 200 ug protein lysate with NeutrAvidin
beads. Note comparable cell-surface levels of
VEGFR-1 and 2 in synectin +/+ and / endothelial
cells. (D) Western blotting of biotinylated cell
extracts with VEGFR2 antibody following precipi-
tation of 200 ug protein lysate with NeutrAvidin
beads. The right panel represents a control for
nonspecific precipitation of VEGFR-2 and shows
that in the absence of biotinylation, VEGFR2 is
not precipitated.
(E–G) VEGFR2 activation. VEGF-A activation of
VEGFR2 Y1175 but not Y1054/1059 is decreased in
synectin/ AEC. Western blotting of total cell
lysates from synectin+/+ and / AEC following serum starvation and stimulation with 50 ng/ml VEGF-A. Note reduced phosphorylation of the Y1175 site in syn-
ectin/ AEC. (G) Quantitative analysis of VEGFR2 Y1175 site phosphorylation based on four independent experiments (mean ± SD, *p < 0.05).
(H) PLCg activation. VEGF-A activation of PLCg in synectin/ AEC. Western blotting of total cell lysates isolated from synectin+/+ and / AEC following serum
starvation and stimulation with 50 ng/ml VEGF-A. Note reduced phosphorylation of PLCg1 on tyrosine 783 in synectin/ AEC. See also Figure S1.
(I)Calciumflux. VEGF-A inducedcalcium levels insynectin/AEC. Calciumflux insynectin +/+ and/AEC was measuredafterovernight starvation incells loadedwith
5 uM Indo-1-AM following VEGF-A (250ng/ml) stimulation. Note reduced calcium flux in synectin / AEC. See also Supplemental Information. (Mean ± SD, *p < 0.05).
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Impaired VEGFR2 Activation in Response to VEGF
Stimulation in Synectin/ Arterial Endothelial Cells
We have previously demonstrated that synectin/ arterial endo-
thelial cells (AEC) have reduced responsiveness to VEGF
stimulation (Chittenden et al., 2006; Prahst et al., 2008). To
further detail this observation and to establish the underlying
cause, we examined VEGF signaling responses and VEGFR2
activation in synectin/ and wild-type AEC.
VEGF stimulation of synectin/ AEC resulted in decreased
activation of key downstream signaling effects including activa-
tion of p42/44 MAPK (ERK-1/2) (Figures 1A and 1B). To explore
the reason for this finding, we first examined total and cell
surface expression of VEGF receptors R1 and R2 in AEC derived
from synectin/ and littermate synectin+/+ mice. No significant
differences in receptor expression were noted by western blot-
ting of total cell lysates cell-surface biotinylated proteins (Fig-
ures 1C and 1D or Figures 1E and 1F).
Since VEGFR2 phosphorylation on key tyrosine residues is
necessary for activation of VEGF signaling, we next examined
the status of Y1054 (a marker of general VEGFR2 activation)
and Y1175 (PLCg/MAPK and PI3K activation site). There were
no significant changes in Y1054 phosphorylation, suggesting that
VEGFR2 was dimerizing and phosphorylating itself (Figure 1E).
However, there was a pronounced reduction in Y1175 phosphor-
ylation, corresponding to observed decreases in p42/44 MAPK
activation (Figures 1F and 1G).714 Developmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier InTo further confirm these changes in VEGFR2 phosphorylation,
we have examined additional downstream signaling events. In
particular, reduced phosphorylation of Y1175 can be expected
to result in decreased activation of PLCg, thereby leading to
a decrease in the rise of intracellular calcium. Indeed, western
blotting demonstrated reduced PLCg phosphorylation (Fig-
ure 1H, Figure S1A, and Supplemental Information) and reduced
VEGF-induced Ca2+ flux (Figure 1I).
Myosin-VI Is a Synectin Binding Partner Involved in
Regulation of VEGFR2 Activation
We next sought to identify synectin binding partners responsible
for regulation of VEGFR2 activity. Since synectin binds neuropilin
and neuropilin signaling is impaired in synectin null endothelial
cells (Prahst et al., 2008), it is possible that the lack of this
interaction is responsible for decreased VEGFR2 activation in
synectin/ AEC. To evaluate this possibility, we examined
ERK1/2 activation following treatment with VEGF-D, a VEGF
family member that signals via VEGFR2 in a neuropilin-indepen-
dent manner. Similar to VEGF-A, VEGF-D treatment resulted in
reduced activation of p42/44 MAPK and Akt in synectin/
AEC (Figure S1B), suggesting that defective VEGFR2 signaling
in synectin/ AEC is not explained by the lack of a neuropilin-
1-synectin interaction.
Synectin can bind other cytoplasmic proteins via its PDZ
domain and it also binds myosin-VI. To further evaluate potential
contributions of synectin binding proteins to impaired VEGF
signaling, synectin/ AEC were transduced with an adenoviralc.
Figure 2. Role of Synectin-Interacting
Proteins in VEGF Signaling
(A–C) Synectin rescue of VEGF signaling in syn-
ectin/ AEC. Synectin/ AEC were transduced
with adenovirus containing either GFP, full-length
synectin (Ad-Syn, [A]), synectin with a mutant
PDZ domain (Ad-Syn-PDZ, [B]) or synectin with
a mutant myosin-VI binding site (Ad-Syn-MVI,
[C]) for 2 days, starved, and stimulated with
50ng/ml VEGF-A. Western blotting of total cell
lysates with pErk(Thr202/Tyr204) and pVEGFR-
2(Tyr1175) shows that expression of Ad-Syn but
not Ad-Syn-PDZ or Ad-Syn-MVI restores
VEGF activation of VEGFR2 and ERK in syn-
ectin/ AEC.
(D–F) VEGF-A activation of p44/42 MAP kinase
and VEGFR2 is reduced in myosin-VI/ AEC.
Western blotting of total cell lysates isolated from
myosin-VI+/+ and / AEC. Confluent, serum-
starved cells were stimulated with 50 ng/ml
VEGF-A and phosphorylation of ERK1/2 and
VEGF-R2 Y1175 was then determined. Note
reduced activation of both proteins. Quantification
of ERK activation (E) and VEGFR2 Y1175 (F) was
carried out on the basis of four independent exper-
iments (Mean ± SD, *p < 0.05).
Developmental Cell
VEGF Receptor 2 Endocytosis and Signalingconstruct carrying either a full-length wild-type synectin cDNA
(Ad-Syn), a synectin construct with a mutated PDZ domain (Ad-
Syn-PDZ) or deleted myosin-VI-binding domain (Ad-Syn-
MVI). Transduction of synectin/ AEC with Ad-Syn virus fully
restored Y1175 site phosphorylation and Erk-1/2 activation by
VEGF (Figure 2A). On the other hand, transduction with either
Ad-Syn-PDZ (Figure 2B) or Ad-Syn-MVI (Figure 2C) constructs
did not restore Erk-1/2 activation or Y1175 phosphorylation.
To confirm that myosin-VI is indeed involved in regulation of
VEGF signaling, we examined VEGF-dependent endothelial
cell responses in myosin-VI/ AEC. Following treatment with
VEGF-A, we observed decreased Erk-1/2 activation (Figures
2D and 2E) and reduced phosphorylation of VEGFR2 Y1175 site
(Figures 2D and 2F) in myosin-VI/ compared to myosin-VI+/+
AEC.Myosin-VI-Synectin Complex Regulates VEGFR2
Endocytosis
We then addressed the mechanism of myosin-VI-dependent
regulation of VEGF signaling. Since both synectin and myosin
VI are involved in intracellular transport of endocytic vesicles,
we examined whether alterations in VEGFR2 endocytic
trafficking may be responsible for the observed VEGF signaling
abnormalities in synectin/ and myosin-VI/ AEC.
Cell-surface VEGFR2 on synectin/, myosin-VI /, and
control AEC were labeled with biotin and the cells were then
exposed to VEGF-A165. At fixed time intervals, cell lysates
were prepared and the amount of internalized VEGFR2 was
determined by western blotting (Figure 3A). There were no
significant differences in VEGFR2 internalization between synec-
tin and myosin-VI null AEC and normal AEC, suggesting that
neither protein was involved in the receptor internalization.
FACS analysis of VEGFR2 uptake from the cell surface afterDeveVEGF stimulation in synectin/ and +/+ AEC confirmed these
observations (Figure S2 and Supplemental Information).
We next examined the transport of VEGFR2-containing
endosomes using wide-field microscopy. Five minutes following
VEGF stimulation of wild-type AEC, VEGFR2 was readily detect-
able in association with the earliest population of endosomes
defined by the presence of EEA1, and by 15 min, over 50% of
endocytosed receptors were detected in that endosomal
compartment (Figures 3B and 3C). Remarkably, there was
a pronounced delay in association of VEGFR2 with EEA1-postive
endosomes in both synectin/ (Figures 3B and 3C) and myosin-
VI/ (Figures 3B and 3D) AEC, suggesting that the absence of
either synectin or myosin-VI interfered with trafficking of very
early endosomes containing VEGFR2.
To examine the reason for this delayed association of
VEGFR2-containing endosomes with EEA1 endosomes, we
evaluated the motility of VEGFR2 vesicles using live-cell imaging.
After VEGF treatment, the speed of movement and the
mean step increment of VEGFR2-containing endosomes
were significantly decreased in synectin/ AEC (Figure 3E)
and myosin-VI/ AEC (data not shown), in agreement with
the decrease previously observed in myosin-VI null cells
(Aschenbrenner et al., 2004).
To further explore how VEGFR2 endocytic trafficking affects
its signaling, we knocked down two Rab GTPases responsible
for either late endosomal recycling to the plasma membrane
(Rab11) or for movement of endosomes to the lysosomes
(Rab7) in AEC. In both cases, there was a significant increase
in VEGF-induced P-ERK activation (Figure 4D) consistent with
the hypothesis that the VEGFR2-containing complex remained
in the cytoplasm for an extended period of time. At the same
time, we also observed decreased association of VEGFR2 endo-
somes with the Rab7- or Rab11-positive compartment (Figures
4A–4C) in synectin/ AEC.lopmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Inc. 715
Figure 3. VEGFR-2Trafficking in Synectin/
and MyosinVI/ Primary Endothelial Cells
(A) VEGFR-2 internalization is similar in synectin
and myosin-VI+/+ and / endothelial cells.
Confluent, serum-starved cells were surface
labeled with biotin and stimulated with VEGF-A.
After stripping remaining cell-surface biotin, cell
lysates were precipitated with NeutrAvidin beads
and western blots probed for VEGFR2 to deter-
mine internalized VEGFR2. See also Figure S2.
(B–D) VEGFR2 trafficking. Serum-starved synec-
tin+/+ and / or myosin-VI-+/+ and / AEC cells
labeled with anti-VEGFR2 (green) were treated
with VEGF-A for 5–30 min and then fixed, perme-
ablized, labeled with anti-EEA1 (red), and
visualized using immunofluorescent microscopy.
Quantification of VEGFR2/EEA1 colocalization at
various time points is shown for synectin+/+
and / AEC in (C) and myosin-VI+/+ and / AEC
in (D). (Mean ± SD, *p < 0.05).
(E) Movement of VEGFR-2 containing vesicles in
synectin/ AEC. Serum-starved cells labeled
with anti-VEGFR-2 were treated with VEGF-A,
and the labeled vesicles tracked by time-lapse
microscopy. Images were acquired every 30 s for
30 min and vesicle mean speed and increment
were determined using Image J. See also
Figure S3. (Mean ± SD, *p < 0.05).
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in Zebrafish and Mice
To demonstrate that the synectin/myosin-VI axis plays a key
role in VEGF signaling, we evaluated the effect of reduced
myosin-VI expression in zebrafish and mice and compared
them to the previously described synectin phenotype. Two
co-orthologs of mammalian myosin-VI have been identified in
zebrafish and their expression pattern has been previously716 Developmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Indescribed (Kappler et al., 2004; Seiler et al., 2004). Myosin-
VIb (myo6b) is expressed exclusively in hair cells of the inner
ear and lateral line organ, while myosin-VIa (myo6a) is more
widely distributed throughout the head and trunk of zebrafish
embryos from 1 to 5 days post fertilization (dpf). A whole-mount
in situ hybridization using a zebrafish myo6a antisense or sense
riboprobe at 28 hr post fertilization (hpf) analysis confirmed
the previously reported ubiquitous expression of myo6a inFigure 4. Role of Rab7/Rab11 GTPases in
VEGFR2 Signaling
(A and B) Colocalization of VEGFR-2 with endo-
some markers. Serum starved synectin+/+ and /
AEC were labeled with anti-VEGFR-2(green) and
then treated with VEGF-A for 30 min, fixed, perme-
ablized, and labeled with anti-Rab11 (red, [A]) or
anti-Rab7 (red, [B]) and processed for confocal
microscopy.
(C) Colocalization of VEGFR-2 with Rab11 and
Rab7 is delayed in synectin null cells. Quantitative
analysis of VEGFR2 colocalization with Rab7 and
Rab11 was carried out using the colocalization
plugin of Image J in at least ten independent fields.
(Mean ± SD, *p < 0.05).
(D) Knockdown of Rab7, Rab11 with siRNA
Results in Prolonged VEGF-A Activation of p44/
42 MAP Kinase. Synectin+/+ endothelial cells
were transfected with anti-Rab7 or Rab11 siRNAs,
and 48 hr later, starved overnight and stimulated
with 50 ng/ml VEGF-A. Western blotting of total
cell lysates with pERK shows increased activation
following Rab7 and Rab 11 knockdowns.
c.
Figure 5. Myo6aKD Impairs Arterial Development in Zebrafish; Functional Effects of Mysosin VI Gene Disruption in Mice
(A and B) Transverse section through the trunk of a 28 hpf zebrafish embryo stained by whole-mount in situ hybridization using a myo6a specific antisense (A) or
sense (B) riboprobe. Myo6a expression was observed in the neural tube (NT), somites (S), and both the dorsal aorta (black arrow) and posterior cardinal vein (white
arrow). The observed expression pattern is specific, as no signal was observed upon hybridization using the sense probe.
(C and D) Dorsal view of 16 hpf Tg(fli1:EGFP)y1 embryo, head on top. In control embryos (C), GFP+ angioblasts migrated in an ordered anteroposteriorly directed
zipper-like pattern from the lateral plate mesoderm toward the midline, where they assembled into the primitive axial vessels. In contrast, in myo6aKD embryos (D),
a portion of angioblasts (arrows) stalled along their lateromedial movement and others failed to maintain their correct stereotyped trajectory, resulting in appar-
ently chaotic migration pattern.
(E and F) Transverse sections through the trunk of Tg(fli1:EGFP)y1embryos of 30 hpf, following a whole-mount immunostaining using an anti-GFP antibody (green)
and counterstained with DAPI (blue); head on top. Compared to control embryos (E and E0), myo6aKD embryos had a strikingly thinner dorsal aorta (arrow) with an
obvious reduced lumen size, while the posterior cardinal vein (arrowhead) remained unaffected (F and F0). (E0) and (F0) are magnifications of the axial vessels in (E)
and (F), respectively.
(G and H) Lateral view on a trunk segment of Tg(fli1:EGFP)y1embryos at 40 hpf ; head to the left. In control embryos (G), ISVs sprouted bilaterally from the dorsal
aorta adjacent to the ventral somite boundaries and navigated upwards to the laterodorsal roof of the neural tube, where they split, elongated, and fused to form
the DLAV. However, in myo6aKD embryos (H), ISVs often consisted of slender endothelial cells (arrowheads) and/or stalled along their dorsal trajectory (arrows),
thereby impairing proper DLAV formation (asteriks).
Scale bars represent 10 mm in (A), (B), and (E–F0) and 5 mm in (C), (D), (G), (H). See also Figures S3 and S4.
(I and J) Representative reconstructed micro-CT images of whole kidneys (16 mm resolution; n = 3) from age- and gender-matched (I) myosinVI+/+ and (J)
myosinVI/ mice. Note marked reduction in branching in myosinVI/ mice.
(K) Quantitative analysis of micro-CT images indicates a marked decrease in total number of <100 mm diameter vessels in myosinVI/ mice (white bars) relative to
myosinVI+/+ mice (black bars). (Mean ± SEM, *p < 0.05).
(L) Quantitative analysis of laser Doppler images indicates significant alterations in hindlimb reperfusion 14 days after femoral artery ligation in myosinVI/ mice
(white bars) relative to myosinVI+/+ mice (black bars). (Mean ± SEM, *p < 0.05).
Developmental Cell
VEGF Receptor 2 Endocytosis and Signalingneural tube and somites (Figures 5A and 5B). Moreover, the
dorsal aorta and posterior cardinal vein expressed myo6a
(Figures 5A and 5B), similar to the expression of synectin in
zebrafish embryos (Chittenden et al., 2006).DeveMyo6a Knockdown Phenocopies Synectin Knockdown
in Arterial Development
We then examined whether myo6a knockdown phenocopies the
arterial defects observed after synectin knockdown. To that end,lopmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Inc. 717
Developmental Cell
VEGF Receptor 2 Endocytosis and Signalingwe injected in 1 cell stage embryos themyo6a-specific antisense
morpholino oligonucleotide Myo6a-ATG1 that selectively targets
the myo6a translation initiation site (Supplementary Information).
Using an established luciferase fusion reporter assay, Myo6a-
ATG1 dose dependently suppressed translation of the reporter,
indicating that it was effective, whereas the inverted control
morpholino Myo6a-Ctr was ineffective, even at the highest
dose tested (Figure S3A). Macroscopic inspection revealed
that Myo6a-ATG1 dose dependently affected the morphological
integrity of the injected embryos. Upon injection of a maximal
dose (10.5 ng per embryo), 36% of myo6a knockdown
(myo6aKD) embryos developed deformities or died during the
first two dpf; these embryos were excluded. The remainder of
myo6aKD embryos had a normal to slightly curved or shortened
body shape; blood flow in their axial and intersomitic vessels
was sluggish or absent by 2 dpf. Thereafter, most myo6aKD
embryos started to develop pericardial edema.
To visualize the vascular defects in myo6aKD embryos in
more detail, we knocked down myo6a in Tg(Fli1:EGFP)y1 zebra-
fish. In Myo6a-Ctr and buffer-injected control embryos, blood
vessels developed normally (Figures 5C, 5E, and 5G). At 16
hpf, angioblasts in control embryos migrated from the lateral
plate mesoderm to the midline in an ordered zipper-like
pattern, proceeding in an anteroposterior direction (Figure 5C,
Table S1). These endothelial progenitors assembled in a primi-
tive vascular cord, which then developed into a luminizied
dorsal aorta and posterior cardinal vein by 24 hpf. In 32% of
myo6aKD embryos, a fraction of angioblasts stalled along their
path toward the midline at 16 hpf, while others appeared to
migrate chaotically in a disorganized zipper-like pattern
(Figure 5D; Table S1). This abnormal migration of endothelial
progenitors impaired dorsal aorta morphogenesis. Up to 77%
of myo6aKD embryos developed an abnormally thin aorta with
a substantially reduced lumen size, appearing as a cord-like
structure, while the posterior cardinal vein developed normally
at 30 hpf (Table S1). Whole-mount immunostaining for GFP re-
vealed a patent posterior cardinal vein in control and myo6aKD
embryos (Figures 5E and 5F), while the aortic lumen was abnor-
mally small in myo6aKD embryos (Figures 5E and 5F). Overall,
the aberrant angioblast migration and impaired formation of
the axial artery in myo6aKD embryos closely resembled the
early vessel defects in synectinKD embryos (Chittenden et al.,
2006).
When analyzing subsequent stages of vessel development,
we observed that, in control embryos, primary (arterial) ISVs
branched off from the aorta at 20 hpf and navigated dorsally
up to the dorsolateral roof of the neural tube, where they split
into a caudal and rostral branch, elongated, and fused with
branches of other segments to form the dorsal longitudinal anas-
tamotic vessels (DLAV) by 48 hpf (Figure 5G, Table S1). In
myo6aKD embryos, initial ISV sprouting was normal and
occurred at the proper designated aortic sites. In synectinKD
embryos, a fraction of ISVs failed to branch off from the aorta
(Chittenden et al., 2006). By contrast, all ISVs branched off nor-
mally from the aorta in myo6aKD embryos, but in 48% of mor-
phants, at least 5 of all ISVs stalled along their dorsal trajectory
and failed to reach the roof of the neural tube, thereby partially
impairing DLAV formation (Figure 5H, Table S1). Also, endothelial
cells of ISVs often appeared abnormally slender (Figure 5H).718 Developmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier InThus, the ISV defects in myo6aKD embryos are qualitatively
similar, though quantitatively less severe than those induced
by synectin knockdown. Altogether, the impaired formation of
the dorsal aorta and its arterial ISV sprouts in myo6aKD zebrafish
embryos nearly phenocopied the arterial defects upon synectin
knockdown. All blood vessel defects described were induced
by Myo6a-ATG1 in a dose-dependent manner (Table S1). More-
over, this vascular phenotype was specific, since another
nonoverlapping morpholino targeting the translational start site
of myo6a, Myo6a-ATG2, which dose dependently suppressed
translation of the luciferase fusion reporter (Figure S3), caused
indistinguishable vascular defects (Table S1).Myo6aKD Causes Similar Arterial Cell Defects
as SynectinKD in Zebrafish
We previously demonstrated that synectin knockdown reduces
the proliferation of arterial endothelial cells (Chittenden et al.,
2006). To assess whether knockdown of myo6a caused compa-
rable defects, we measured arterial proliferation in myo6aKD
embryos, using similar techniques as used for synectin knock-
down. Tg(Fli1:EGFP)y1 embryos were incubated with BrdU at
20 hpf and allowed to grow until 30 hpf, after which arterial and
venous GFP+BrdU+ endothelial cells were counted (Figure S4).
While the number of proliferating venous endothelial cells was
unaffected (1.63 ± 0.12 cells/section in myo6aKD embryos versus
1.61 ± 0.14 cells/section in control embryos; n = 9; p = 0.83),
endothelial proliferation was reduced in the aorta and ISVs of
myo6aKD embryos (1.41 ± 0.16 cells/section in myo6aKD embryos
versus 1.95 ± 0.18 cells/section in controls; n = 9; p < 0.05). These
results suggest that knockdown of myo6a—albeit somewhat less
than knockdown of synectin—impairs migration and proliferation
of arterial but not venous endothelial cells.Myosin-VI Knockout Impairs Arterial Morphogenesis
in Mice
Unlike zebrafish, only one myosin-VI gene is present in mice.
Myosin-VI null mice, similar to synectin null mice, were smaller
than their littermate wild-type counterparts (17.9 ± 2.9 g versus
22.5 ± 3.9 g, p < 0.01). Micro-CT evaluation of vascular density
demonstrated a smaller number of arteries in the renal (Figures
5I and 5J) and peripheral circulations (Figure 5K), similar to find-
ings in synectin knockout mice.
To evaluate the effect of myosin-VI deletion on arterial
morphogenesis in adult tissues, the common femoral artery of
myosin-VI/ and control littermate mice was ligated and the
flow recovery was measured over time using laser-Doppler
as previously described. Similar to synectin/ mice, myosin-
VI/ mice demonstrated impaired recovery of lower limb blood
flow consistent with impaired arterial growth (Figure 5L).VEGFR2 Dephosphorylation in Synectin/
and Myosin-VI/ Endothelial Cells
The delayed trafficking of VEGFR2 endosomes away
from the plasma membrane and the observed increase in
dephosphorylation of VEGFR2 in both synectin/ and myosin-
VI/ endothelial cells may be due to prolonged exposure of acti-
vated VEGFR2 to membrane-resident or perimembrane tyrosine
phosphatases in these cells. To test this possibility and toc.
Figure 6. Effect of Phosphatase Knock-
down on VEGF Signaling
(A and B) PTP1B knockdown increases VEGF
signaling in synectin/ AEC. Synectin/ AEC
were transfected with the siRNAs indicated for 2
days, starved, and stimulated with 50 ng/ml
VEGF-A. Western blotting of total cell lysates
with pErk and pVEGFR2(Y1175) shows increased
phosphorylation after PTP1b knockdown (A).
Quantification of pERK activation is shown in (B).
See also Figure S6. (Mean ± SEM, *p < 0.05).
(C) Effect of PTP1B knockdown on AEC migration.
The relative distance migrated by AEC from syn-
ectin+/+ and / mice grown on fibronectin-coated
dishes was measured 8 hr following ‘‘wounding’’
of a confluent monolayer and stimulation with
0.5%FBS or 50 ng/ml VEGF-A in the presence of
either control siRNA or PTP1b siRNA. Note
increased extent of migration of synectin/ cells
in response to VEGF following treatment with
PTP1B siRNA. Means +/ SD, * = p < 0.05. Stippled bars, synectin+/+ AEC treated with control siRNA; gray bars, synectin+/+ AEC with PTP1b siRNA; black
bars, synectin/ AEC with control siRNA; white bars, synectin/ AEC with PTP1b siRNA.
(D) Effect of Co-Knockdown of Myo6a and Ptp1b in Zebrafish. Quantitative analysis of arterial defects in morphant embryos revealed that Ptp1b-ATG partially
rescues the myo6a knockdown phenotype in a dose-dependent manner. Single ptp1bKD (6ng Ptp1b-ATG) does not induce vascular defects. Dark blue bars indi-
cate single myo6aKD (10.5 ng Myo6a-ATG1); blue and light blue bars indicate double ptp1bKD:myo6aKD (10.5ng Myo6a-ATG1 combined with 3 or 6 ng Ptp1b-
ATG, respectively). (*p < 0.05; **p < 0.001).
Developmental Cell
VEGF Receptor 2 Endocytosis and Signalingidentify the phosphatase involved, we used siRNA to knockdown
four different phosphotyrosine phosphatases in synectin/ AEC
(Figure S5A) while measuring ERK1/2 activation in response to
VEGF. Knockdown of PTP1b was the most effective in restoring
ERK activation in synectin/ AEC (Figures 6A and 6B). Further-
more, there was a marked restoration of VEGFR2 phosphoryla-
tion at Y1175 (Figure 6A). However, knockdown of these
phosphatases in control (wild-type) AEC had no additional effect
on ERK1/2 phosphorylation (Figure S5B). Of interest, PTP1b was
expressed equally in arterial and venous endothelial cells and
synectin deletion had no effect on its expression (Figure S5C).
To confirm the physiologic significance of restoration of
VEGFR2 Y1175 phosphorylation, wild-type and synectin/ AEC
were exposed to either PTP1b or control siRNA and the migra-
tion response to VEGF was measured. While synectin/ AEC
treated with control siRNA migrated significantly less than
control AEC, exposure to PTP1b siRNA significantly increased
migration, restoring it to control cell levels, consistent with the
observed VEGFR2 Y1175 site activation (Figure 6C).
Knockdown of Ptp1B Rescues the Arterial Phenotype
upon Myo6a Knockdown
In line with our in vitro findings, we anticipated that the arterial
defects upon myo6a knockdown were the consequence of
a prolonged exposure of VEGFR2 to the phosphatase activity
of PTP1b, thereby inhibiting downstream VEGF signaling. We
therefore silenced ptp1b in Tg(Fli1:EGFP)y1 zebrafish embryos
by using a ptp1b-specific morpholino, Ptp1b-ATG, which
targets the ptp1b translation initiation site. Similar to the
myo6a targeting morpholinos, Ptp1b-ATG dose dependently
blocked translation of the reporter in a chimeric luciferase
reporter assay (Figure S3B).
Consistent with previous reports (van der Sar et al., 1999),
a dose of 6 ng Ptp1b-ATG did not induce gross morphological
deformities or vessel defects (thin dorsal aorta, arrested ISVDeveformation), neither did it impair circulation by 2 dpf (data not
shown; n = 147). However, in coinjection experiments, Ptp1B-
ATG partially rescued the characteristic vascular defects,
induced by a maximal dose of Myo6a-ATG1 (data not shown).
In embryos injected with 10.5 ng Myo6A-ATG1, 71% and 62%
of the embryos exhibited a thin aorta or arrested ISVs, respec-
tively (n = 90). By contrast, in embryos coinjected with 10.5 ng
Myo6A-ATG1 and 6 ng Ptp1b-ATG, only 50% and 31% of
embryos exhibited corresponding vascular defects (Figure 6D,
n = 179; p < 0.05 and p < 0.001, respectively, by Chi-square
analysis). Qualitatively similar results were obtained when
a lower dose of 3 ng Ptp1b-ATG was coinjected with 10.5 ng
Myo6A-ATG1 (data not shown). Cosilencing of ptp1b and
myo6a also prolonged embryonic survival: of 186 myo6aKD
embryos, 51.6% were severely malformed or deceased by
2 dpf. Corresponding values were 42.4% for ptp1bKD:myo6aKD
embryos (3 ng Ptp1b-ATG; n = 203; p < 0.05) and 24.5% for
ptp1bKD:myo6aKD embryos (6 ng Ptp1b-ATG; n = 237;
p < 0.001). Partial rescue of the dorsal aorta and ISV defects
by myo6a knockdown was also achieved by coinjection of
another ptp1b-specific morpholino, Ptp1b-Splice (n = 144;
p < 0.05 for both vascular phenotypes). This Ptp1b-Splice
morpholino targets the splice site between the first exon and
intron of ptp1b and efficiently blocks splicing as evidenced
by PCR amplification of the ptp1b region spanning the
first intron boundary (Figure S3C). In contrast, similar doses
of the control morpholino Ptp1b-Ctr failed to rescue the
myo6a knockdown phenotype: of ptp1bCrl:myo6aKD embryos,
72.7% and 62.8% suffered dorsal aorta and ISV defects,
respectively (n = 161).
Knockdown of Ptp1B Rescues the Arterial Phenotype
in Synectin Null Mice
We next tested the effectiveness of PTP1b suppression on resto-
ration of VEGFR2 signaling and arterial morphogenesis inlopmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Inc. 719
Figure 7. Functional Effects of PTP1B Inhi-
bition in Synectin/ Mice
(A) Laser Doppler analysis of blood flow. Syn-
ectin/ and +/+ mice were subjected to common
femoral artery ligation and PTP1b inhibitor or
vehicle were administered as described. The
graph shows blood flow in the ischemic foot
expressed as a ratio to flow in the normal foot.
Note a significant increase in flow in PTP1b inhib-
itor treated synectin/ mice. (Mean ± SEM,
*p < 0.05, n = 7 per group).
(B and C) Micro CT analysis of arterial vasculature
development. Graph (B) shows quantitative anal-
ysis of arterial vasculature above the knee in
synectin/ and +/+ mice 14 days after common
femoral artery ligation and treatment with either
PTP1b inhibitor or vehicle (Mean ± SEM,
*p < 0.05). Note significant increase in smaller
size arteries in PTP1b inhibitor-treated synectin/
mice. Representative micro-CT images are
shown in (C).
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subjected to common femoral artery ligation, while a PTP1b
inhibitor was administered daily by oral gavage. Assessment of
distal limb blood flow using laser-Doppler imaging demonstrated
markedly accelerated recovery in the inhibitor treated syn-
ectin/ mice, with flow recovering to levels seen in control
mice (Figure 7A). Control animals treated with the inhibitor
demonstrated a tendency toward higher flows than untreated
controls; however, they only reached statistical significance on
day 7. To evaluate the extent of arteriogenesis, micro-CT images
of the limb circulation were obtained (Figure 7C). There was
a highly statistically significant increase in small (<168 mm)
arteries in the inhibitor treated synectin/ mice (Figure 7B),
with most of the new arteries appearing in the nonischemic thigh
area (Figure 7C).
DISCUSSION
Recent studies have demonstrated that tyrosine kinase recep-
tors in general, and VEGFR2 specifically, signal not only from
the plasma cell membrane but from endosomal compartments
(Di Fiore and De Camilli, 2001; von Zastrow and Sorkin, 2007)
and that disruption of endocytosis may affect receptor signaling
(Lampugnani et al., 2006). However, specific molecular mecha-
nisms involved in this endocytosis-dependent regulation of
receptor signaling have not been established. Here, we report
that trafficking of VEGFR2 from the plasma membrane to
EEA1-positive endosomes requires synectin-myosin-VI-depen-
dent retrograde transport through the cortical zone and that
any defects in this transport results in PTP1b-dependent
dephosphorylation of the Y1175 site. This, in turn, leads to defec-
tive arterial morphogenesis both during embryonic development
and in adult tissues.
VEGFR2 signaling is enabled by phosphorylation of several crit-
ical cytoplasmic domain tyrosine residues following VEGF-
induced dimerization, while a number of phosphotyrosine phos-
phatases are thought to be capable of extinguishing it. To date,720 Developmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier InPTP1b (Nakamura et al., 2008), TC-PTP (Mattila et al., 2008), VE-
PTP (Mellberg et al., 2009; Nottebaum et al., 2008), Dep-1/
CD148 (Lampugnani et al., 2003), and Shp2 have all been reported
to variously regulate VEGFR2 signaling (Mitola et al., 2006).
In particular, PTP1b has been reported to specifically dephos-
phorylate the Y1175 site, thereby affecting activation of the PLCg-
MAPK pathway (Nakamura et al., 2008). PTP1b is a small
cytoplasmic PTP (Bourdeau et al., 2005) that resides on the
cytoplasmic surface of the endoplasmic reticulum. This is in
direct distinction to another small cytoplasmic PTP, TC-PTP,
that dephosphorylates VEGFR2 at Y1054/1059 (TK activation site)
and Y1214 (p38MAPK activation site) sites while not affecting
Y1175.
PTP1b expression is controlled by a number of factors such as
ischemia and hypoxia and increased expression is noted in
insulin-resistant states and obesity (Bourdeau et al., 2005),
conditions associated with decreased VEGF activity. PTP1b-
catalyzed dephosphorylation requires endocytosis of the
receptors and occurs at specific sites on the surface of the endo-
plasmic reticulum (Haj et al., 2002). PTP1b coprecipitates with
VEGFR2 (Nakamura et al., 2008), suggesting either a physical
interaction between the two proteins or their presence in the
same protein complex. A decrease in PTP1b expression results
in increased ERK1/2 activation, while an increase in its expres-
sion suppresses it (Nakamura et al., 2008). This suggests that
PTP1b activity specifically affects the Y1175 site phosphorylation
that is required for binding of PLCg and subsequent activation
of the RAF-MEK-ERK cascade.
PTP1b effects are not restricted to VEGFR2. Of interest to the
current study is the observation that PTP1b inhibits EGF-R
signaling from the endocytic compartment (Eden et al., 2009)
by regulating phosphorylation of the PLCg binding site (Y992)
in EGFR (Milarski et al., 1993).
Transmembrane receptor type PTPs also have been reported
to regulate VEGFR2 activity. Thus, DEP1/CD148, by binding to
b-catenin and p120-catenin, associates with VE-cadherin-
VEGFR2 complex on the plasma cell membrane andc.
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tion of DEP1 leads to increased tyrosine phosphorylation of all
major VEGFR2 autophosphorylation sites but surprisingly
results only in activation of Src activity without an overall stim-
ulation of VEGF-dependent signaling (Chabot et al., 2009). VE-
PTP, a transmembrane PTP structurally related to DEP-1, is
expressed in the vasculature during development with
a preferential expression in arterial endothelium. A reduction
in VEGFR2-VE-PTP association leads to a striking increase in
receptor phosphorylation at most sites, with the possible
exception of Y1214 (Mellberg et al., 2009).
Thus, while various PTPs are able to affect VEGFR2 signaling,
their sites of action are distinct and specific for the each enzyme.
Since VEGFR2 endocytosis is thought to play a major role in
regulation of its signaling, it is important to link the two events
in terms of molecular mechanism. VEGFR2 internalizes
predominantly in a clathrin-dependent manner in EEA1-positive
endosomes and to a very low extent via caveolin or lipid raft
pathways. Furthermore, active PLCg codistributes with internal-
ized VEGFR2, suggesting that Y1175 site phosphorylation either
occurs in or is maintained in endosomes. Reduction in clathrin
expression results in decreased VEGFR2 and ERK1/2 phosphor-
ylation (Lampugnani et al., 2006).
While little is known about the transport of newly endocytosed
proteins in clathrin-coated vesicles to early endosomes, recent
studies have implicated synectin as an important regulator of
this step. Thus, synectin is involved in endocytosis of TrkA (Lin
et al., 2006; Lou et al., 2001; Varsano et al., 2006), Glut1 (Wieman
et al., 2009), and neuropilin-1 (Salikhova et al., 2008). Synectin
accomplishes this in part by binding to APPL (adaptor protein,
phosphotyrosine interaction, PH domain, and leucine zipper
containing), a protein that recruits RAB5 to enlarged APPL-asso-
ciated membrane structures, a key event in regulation of signal
transduction (Chial et al., 2008; Miaczynska et al., 2004; Zoncu
et al., 2009), and in part by binding to myosin-VI.
Myosin-VI, unlike other myosins, is able to move toward the
minus end of actin filaments, and as a result it has been impli-
cated in a variety of cellular processes including endocytosis,
secretion, and membrane ruffling (Buss and Kendrick-Jones,
2008). Furthermore, myosin-VI colocalizes with synectin in
uncoated endocytic vesicles and is involved in their movement
through the cortical actin filament network below the plasma
cell membrane (Chibalina et al., 2007).
In the present study, we extend these observations by demon-
strating that the synectin-myosin-VI dependent transport of
VEGFR2-containing endosomes plays a key role in the regulation
of VEGF signaling and arterial specification. Homozygous
disruption of both synectin and myosin-VI expression in mice
or knockdown of their expression in zebrafish results in similar
phenotypes highlighted by decreased arterial morphogenesis,
including reduced size of the arterial vasculature, reduced
branching, and the inability to restore arterial perfusion in adult
tissues. These phenotypes can be traced to reduced activation
of the Y1175 site on VEGFR2 that is specifically involved in activa-
tion of the PLCg-MAPK pathway that has been implicated in
arterial morphogenesis (Ren et al., 2010). In turn, the proximal
cause of reduced Y1175 phosphorylation is slow trafficking of
VEGFR2 endosomes from the cortical zone, where it is exposed
to PTP1b that dephosphorylates this site. The impairment ofDeveVEGF signaling in this case is not complete, as eventually
some VEGFR2 endosomes are able to move away from the
plasma cell membrane and some degree of PLCg and ERK-1/2
activation is maintained. As a result, the deletion of either synec-
tin or myosin-VI is not lethal but both are associated with
impaired arterial morphogenesis.
The links between these events are demonstrated by the
ability of full-length synectin to restore the phenotype in synectin
null endothelial cells, while mutants with disrupted myosin-VI or
PDZ binding sites have no such activity. The latter mutant
prevents synectin from binding to APPL and is consistent with
a report of suppressed Akt phosphorylation that depends on
Y1175 phosphorylation (Saito et al., 2007). The link to PTP1b is
suggested by restoration of VEGF signaling in synectin null cells
following suppression of PTP1b expression, while knockdown of
other VEGFR2-associated PTPs have less effect. Furthermore,
arterial morphogenesis was restored in adult synectin/ mice
following suppression of PTP1b activity using a specific inhibitor
in an ischemic setting. Finally, PTP1b knockdown largely
restored developmental arterial morphogenesis abnormalities
in myosin-VIKD zebrafish.
The findings in this study suggest the following sequence of
events: following VEGF binding, VEGFR2 is activated as demon-
strated by phosphorylation of Y1054/1059 sites. This in turn leads
to autophosphorylation of other VEGFR2 tyrosines. The newly
activated receptors are then endocytosed, enter the submem-
brane space in clathrin-positive vesicles, and bind APPL
(Miaczynska et al., 2004), which in turn binds the synectin-
myosin-VI complex (Lin et al., 2006; Varsano et al., 2006) that
moves VEGFR2 vesicles to EEA1-positive endosomes. At that
point, phosphorylation of the Y1175 becomes manifest, leading
to activation of the PLCg/MAPK and PI3K-Akt cascades. This,
in turn, promotes arteriogenic signaling, likely via activation of
Ets transcription factors (De Val and Black, 2009; Watanabe
et al., 2004).
In the absence of synectin or myosin-VI, the VEGFR2-
containing vesicles spend an excessively long time in the
submembrane region where the Y1175 site is dephosphorylated
by PTP1b, leading to selective downregulation of PI3K/Akt and
MAPK cascades, thus resulting in defective arteriogenesis and
branching morphogenesis. On the other hand, knockdown of
Rab7 or Rab11 expression increases ERK activation, as it forces
the VEGFR2 endosome to spend more time in the ‘‘signaling
compartment’’ of the cytoplasm.
In conclusion, our findings identify the synectin/myosin-VI
complex as a key regulator of arterial morphogenesis and
demonstrate that trafficking of VEGFR2-containing endocytic




The list of antibodies and other reagents is presented in the Supplemental
Information.
Isolation of Murine Arterial and Veinous Endothelial Cells
Primary arterial and venous endothelial cells were isolated from adult mouse
dorsal aorta and vena cava using a protocol similar to that previously
described (Allport et al., 2002).lopmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Inc. 721
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Cells were plated on 10 cm fibronectin-coated dishes, grown to 60%–70%
confluence, and starved for 8 hr in media containing 0.5% FBS. Adenovirus
was added overnight in media containing 0.5% FBS at an MOI of 100, and
the next day media containing 20% FBS was added. After 2–3 days, the cells
were starved overnight in 0.5% FBS and stimulated with VEGF-A165 (50 ng/ml)
for 5 min, then harvested with RIPA lysis buffer.
siRNA Transfection of Endothelial Cells
siRNA (QIAGEN) (200 pmoles/dish) in 1 ml media containing 0.5% FBS and
Targefect siRNA suspension (Targeting Systems) was added to cells plated
on 6 cm fibronectin-coated dishes at 70%–80% confluent and incubated for
2 hr at 37C. The same procedure was repeated 24 hr later.
Analysis of VEGFR-2 Internalization by Cell-Surface Biotinylation
Cells were grown to confluence on 10 cm fibronectin-coated dishes and
starved overnight in media with 0.5% FBS. After rinsing with cold PBS, cells
were incubated with 5 ml/dish EZ-Link Sulfo-NHS-SS-Biotin (0.25mg/ml) in
PBS at 4C for 30 min, quenched with cold PBS + 50 mM glycine, and
rinsed with cold media with 1% BSA. Cells were then stimulated with VEGF-
A (50ng/ml) at 37C. At predetermined time points, cells were rinsed with
cold PBS and incubated for 20 min on ice with glutathione (45 mM) in
75 mM NaCL, 75 mM NaOH, 1 mM EDTA, 1% BSA. Glutathione was quenched
with cold PBS with iodoacetamide (5 mg/ml). Cells were rinsed with cold PBS
and protein lysates prepared using NP-40 lysis buffer. Lysate (200 mg) was
immunoprecipitated with 50 ml NeutrAvidin beads at 4C overnight, then rinsed
with 500 ml NP-40 lysis buffer and resuspended in 60 ml 23 Lamelli’s SDS-
sample buffer. Samples were analyzed by SDS-PAGE followed by western
blotting with anti-VEGFR2 (Cell Signaling).
Endothelial Cell Migration Assay
Cell migration was measured by ‘‘wounding’’ assays, as previously described
(Chittenden et al., 2006) Cells were treated with medium containing 0.5% FBS,
20% FBS, or 0.5% FBS plus VEGF (50 ng/ml). An average of at least 10
measurements per condition from 2 individual wells were analyzed for each
experiment.
Colocalization of VEGFR-2 and EEA1, Rab7, and Rab11
Cells were plated on fibronectin-coated glass-bottom plates (MatTek) and
starved overnight with 0.5%FBS. All antibody labelings were carried out on
ice. Cells were labeled with rat anti-mouse VEGFR-2 (10 mg/ml) primary anti-
body for 15 min, rinsed with cold PBS, followed by chick anti-rat alexa488
secondary antibody for 15 min. Cells were then stimulated with VEGF-A165
(50ng/ml) and following incubation at 37C for 0–30 min, cells were washed
with ice-cold PBS (pH 2.5) to remove remaining cell-surface receptors. Cells
were fixed for 10 min at 25C 4% paraformaldehyde and permeablized with
2.5% PFA/0.1% Triton X-100/0.1% NP-40 for 10 min. Cells were then labeled
with goat anti-EEA1 antibody overnight, followed by chick anti-goat alexa647
secondary antibody. Samples were observed under a wide-field fluorescence
microscope (Olympus IX-71) equipped with a Sensicam QE cooled CCD
camera (Cooks), DG-4 xenon arc light source (Sutter), and 603 oil immersion
lens. QED software (Media Cybernetics) was used for image acquisitions. Co-
localization was quantified using the colocalization plugin of Image J. For
colocalization of Rab7 (Rab11), cells were labeled with mouse anti-
Rab7(Rab11) followed by rabbit anti-mouse alexa568 secondary antibody.
Images were acquired by laser-scanning confocal microscopy with X63 objec-
tive (Zeiss LSM 510 Meta).
Live-Cell Microscopic Imaging of VEGFR-2 Containing Vesicles
Cells were labeled with rat anti-mouse monoclonal VEGFR2 (10 mg/ml) primary
antibody for 15 min, rinsed with cold PBS, labeled with chick anti-rat alexa488
secondary antibody for 15 min, and rinsed again with cold PBS. Cells were
placed on the microscope stage and treated with media supplemented with
0.5% FBS and VEGF-A165 (50ng/ml) at 37
C. Time-lapse imaging was done
on an inverted microscope (Olympus IX-71 wide field) equipped with a plexi-
glass-enclosed stage kept at 37C and 5% CO2. Images were acquired by
a cooled software-controlled (QED, Media Cybernetics) charge-coupled
device camera (SensiCam, Cooke Corp.) using a filter and a 603 oil immersion722 Developmental Cell 18, 713–724, May 18, 2010 ª2010 Elsevier Inobjective lens (Olympus). Images were acquired every 30 s for 30 min following
VEGF stimulation. Images were processed using ImageJ, and individual vesi-
cles were tracked using the ‘‘manual tracking’’ plugin.
Surgical Hindlimb Ischemia Model
This was done as previously described (Chittenden et al., 2006). Laser-
Doppler flow imaging was carried out using a Moor Infrared Laser Doppler
Imager (LDI; Moor Instruments, Ltd.) at 36.5C to 37.5C under isoflurane
anesthesia. The data were analyzed with Moor LDI image processing software
V3.09 and reported as the ratio of flow in the right/left (R/L) hindlimb.
Micro-CT Angiography
A 1:1 mixture of bismuth (Sigma-Aldrich) and gelatin (ICN Biomedicals) was
used as the vascular contrast agent. The preparation, acquisition, and analysis
of micro-CT images was carried out as previously described (Chittenden et al.,
2006).
PTP1B inhibitor treatment
PTP1B inhibitor was synthesized and provided by Merck Frosst Canada and
used as previously described (Julien et al., 2007). PTP1B compound (or
vehicle) was administered (30 mg/kg body weight) daily by oral gavage with
an injection volume of 10 ml/kg body weight beginning 2 days prior to femoral




Tg(fli1:EGFP)y1 zebrafish (Lawson and Weinstein, 2002) were maintained
under standard laboratory conditions. Embryos were kept in 0.33 Danieau/
PTU (embryo water) at 28C. The following gene-specific and control anti-
sense morpolino oligonucleotides were purchased from Gene Tools (LLC, Cor-
vallis) (see Supplemental Experimental Procedures for sequence details).
Silencing efficiencies of Myo6a-ATG1, Myo6a-ATG2, and Ptp1b-ATG were
determined as previously described using a luciferase reporter assay (Ny et al.,
2005), whereas silencing efficiency of Ptp1b-Splice was evidenced by PCR
amplification of ptp1b-specific sequences, spanning the first intron boundary,
using cDNA from ptp1b-Splice-injected embryos of 2 dpf. Different doses of
morpholinos and, for the rescue experiments, different combinations of mor-
pholinos, were injected into 1–4 cell stage embryos, using procedures as
previously described (Stalmans et al., 2002), and embryos were further incu-
bated in embryo water at 28C until 16 hpf, 30 hpf, and 40 hpf. At these time
points, between 30 and 60 injected embryos per experiment were analyzed.
The penetrance per experiment was scored by counting the affected embryos,
and each experiment was repeated at least three times. All data of myo6a
knockdown shown in the manuscript were obtained after injection of 10.5 ng
of Myo6a-ATG1. Control embryos were injected with injection buffer (0.1%
phenol red, 0.4 M KCl). Confocal imaging of embryos was performed using
a Zeiss laser scanning microscope LSM510 and the 488 nm laser emission
was supplied by an argon laser.
Zebrafish Whole-Mount In Situ Hybridization and Immunostaining
Dechorionated embryos were fixed overnight in 4% paraformaldehyde at 4C.
Whole-mount in situ hybridization was performed as described (Stalmans
et al., 2002), using antisense probes for zebrafish myo6a. Tg(fli1:EGFP)y1
embryos were immunostained as described with rabbit anti-GFP antibody
(Torrey-Pines Biolabs) and mouse anti-BrdU antibody (Santa Cruz
Biotechnology). Stained embryos were first embedded in 1.5% agarose and
subsequently in paraffin and sectioned at 7 mm. Sections were counterstained
with nuclear fast red and DAPI for hybridized and immunostained embryos,
respectively. Analysis was performed using a Zeiss Axia Imager microscope.
Statistical Analysis
Standard deviations are shown as bars in the histograms, except for the hin-
dlimb data, where the error bars represent standard error of the mean
(SEM). Differences were considered statistically significant if p %0.05 by
Student’s two-tailed t test. For the zebrafish analysis, Chi-square analysis
was used to determine whether the fraction of embryos exhibiting a certain
blood vessel phenotype differed between treatment groups.c.
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